Risk Profile of HIPEC

Mortality Risk

Perioperative mortality ranges from 0% to 7% across trials, with recent high-quality studies consistently reporting 0% procedure-related deaths, according to the National Comprehensive Cancer Network 1, 2, 3, 4
The American College of Surgeons recommends that HIPEC be performed at experienced centers with appropriate patient selection to minimize morbidity and mortality 1, 2
The CYTO-CHIP study showed HIPEC added to cytoreductive surgery improved survival without increasing mortality in gastric cancer patients 5, 6
A phase II gastric cancer trial reported 90-day mortality of 0% despite 70% morbidity rate, highlighting the importance of proper patient selection and institutional experience 6, 7

Major complications occur in 9-40% of patients within 30 days of surgery, with significant variation across trials and centers, as reported by the National Comprehensive Cancer Network 1, 2, 3, 8
The Society of Surgical Oncology notes that complication rates have decreased over time at experienced centers as techniques have evolved and institutional experience has grown 1, 4
The M06OVH-OVHIPEC trial showed no difference in grade 3-4 toxicities between HIPEC and control groups, emphasizing the need for careful patient selection and comprehensive perioperative care 1, 2

The American Society of Peritoneal Surface Malignancies recommends that median procedure time ranges from 300-600 minutes, significantly longer than cytoreductive surgery alone, highlighting the need for experienced centers and comprehensive perioperative support 1, 3, 4
Median hospital stay ranges from 8-24 days, though the M06OVH-OVHIPEC trial showed minimal difference, emphasizing the importance of proper patient selection and institutional experience 1, 2, 3

The National Comprehensive Cancer Network recommends that patient selection is paramount, with HIPEC reserved for patients with high-volume intraperitoneal disease or peritoneal carcinomatosis who are at risk for widespread microscopic disease after resection 1, 2, 4
Patients with low peritoneal carcinomatosis index (PCI <7-10) have better outcomes and lower complication rates, as reported by the Society of Surgical Oncology 5, 6
Complete cytoreduction (R0 resection) is essential for benefit to outweigh risks, with incomplete cytoreduction negating survival advantages, according to the American College of Surgeons 5

For ovarian cancer, HIPEC improved survival without increasing toxicity or affecting quality of life in the definitive M06OVH-OVHIPEC trial, as reported by the National Comprehensive Cancer Network 1, 2, 9
For gastric cancer with peritoneal metastases, the CYTO-CHIP study showed HIPEC improved survival without increasing morbidity or mortality, highlighting the importance of proper patient selection and institutional experience 5, 6, 7
A phase II trial reported 70% 90-day morbidity but 0% mortality, emphasizing the need for careful patient selection and comprehensive perioperative care 6, 7, 10